Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 154 articles:
HTML format



Single Articles


    May 2021
  1. IGUCHI T, Kimura G, Fukasawa S, Suzuki H, et al
    Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
    Int J Urol. 2021 May 6. doi: 10.1111/iju.14568.
    PubMed     Abstract available


  2. CLAPS F, Ramirez-Backhaus M, Mir Maresma MC, Gomez-Ferrer A, et al
    Indocyanine green guidance improves the efficiency of extended pelvic lymph node dissection during laparoscopic radical prostatectomy.
    Int J Urol. 2021;28:566-572.
    PubMed     Abstract available


  3. MATTI B, Zargar-Shoshtari K
    Age-adjusted reference values for prostate-specific antigen in a multi-ethnic population.
    Int J Urol. 2021;28:578-583.
    PubMed     Abstract available


  4. LOW AW, Chen K, Tan YG, Ng TK, et al
    Ambulatory robot-assisted laparoscopic radical prostatectomy with extended recovery by total extraperitoneal approach.
    Int J Urol. 2021;28:561-565.
    PubMed     Abstract available


    April 2021
  5. YOSHIDA S, Fujii Y
    Editorial Comment to Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
    Int J Urol. 2021 Apr 22. doi: 10.1111/iju.14578.
    PubMed    


  6. AIZAWA R, Takayama K, Nakamura K, Ogata T, et al
    Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
    Int J Urol. 2021 Apr 2. doi: 10.1111/iju.14567.
    PubMed     Abstract available


  7. TATENUMA T, Makiyama K, Ito Y, Muraoka K, et al
    Correlation of urinary loss rate after catheter removal and long-term urinary continence after robot-assisted laparoscopic radical prostatectomy.
    Int J Urol. 2021;28:440-443.
    PubMed     Abstract available


  8. HAGA N, Miyazaki T, Tsubouchi K, Okabe Y, et al
    Comprehensive approach for preserving cavernous nerves and erectile function after radical prostatectomy in the era of robotic surgery.
    Int J Urol. 2021;28:360-368.
    PubMed     Abstract available


    March 2021
  9. YOSHIDA S, Takahara T, Arita Y, Sakaino S, et al
    Whole-body diffusion-weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond.
    Int J Urol. 2021 Mar 6. doi: 10.1111/iju.14497.
    PubMed     Abstract available


  10. HATAKEYAMA S, Ohyama C
    Editorial Comment to Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.
    Int J Urol. 2021 Mar 4. doi: 10.1111/iju.14539.
    PubMed    


    February 2021
  11. SHIOTA M, Sumikawa R, Onozawa M, Hinotsu S, et al
    Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.
    Int J Urol. 2021 Feb 24. doi: 10.1111/iju.14518.
    PubMed     Abstract available


  12. HAGA N, Miyazaki T, Tsubouchi K, Okabe Y, et al
    Editorial Comment to Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial.
    Int J Urol. 2021 Feb 7. doi: 10.1111/iju.14511.
    PubMed    


  13. MINAGAWA T, Oguchi T, Saitou T, Fukazawa A, et al
    Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial.
    Int J Urol. 2021 Feb 7. doi: 10.1111/iju.14487.
    PubMed     Abstract available


  14. KUSHWAHA B, Devi A, Maikhuri JP, Rajender S, et al
    Inflammation driven tumor-like signaling in prostatic epithelial cells by sexually transmitted Trichomonas vaginalis.
    Int J Urol. 2021;28:225-240.
    PubMed     Abstract available


    January 2021
  15. HASHIMOTO T
    Editorial Comment to Benefits and harms of the new prostate cancer grade grouping on the prediction of long-term oncological outcomes in patients after radical prostatectomy.
    Int J Urol. 2021 Jan 28. doi: 10.1111/iju.14514.
    PubMed    


  16. NAGATA M
    Editorial Comment from Dr Nagata to Diagnostic performance of prostate cancer antigen 3 and the Prostate Health Index in detecting overall and clinically significant prostate cancer in men at first biopsy: A meta-analysis.
    Int J Urol. 2021 Jan 16. doi: 10.1111/iju.14494.
    PubMed    


  17. MILONAS D, Muilwijk T, Venclovas Z, Devos G, et al
    Benefits and harms of the new prostate cancer grade grouping on the prediction of long-term oncological outcomes in patients after radical prostatectomy.
    Int J Urol. 2021 Jan 6. doi: 10.1111/iju.14471.
    PubMed     Abstract available


  18. FALAGARIO UG, Lantz A, Jambor I, Martini A, et al
    Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.
    Int J Urol. 2021;28:47-52.
    PubMed     Abstract available


    December 2020
  19. URABE F
    Editorial Comment from Dr Urabe to Diagnostic performance of prostate cancer antigen 3 and the Prostate Health Index in detecting overall and clinically significant prostate cancer in men at first biopsy: A meta-analysis.
    Int J Urol. 2020 Dec 19. doi: 10.1111/iju.14467.
    PubMed    


  20. JIA W, Wu B, Shao Y, Cao X, et al
    Diagnostic performance of prostate cancer antigen 3 and the Prostate Health Index in detecting overall and clinically significant prostate cancer in men at first biopsy: A meta-analysis.
    Int J Urol. 2020 Dec 18. doi: 10.1111/iju.14464.
    PubMed     Abstract available


  21. SAKAMOTO S
    Editorial Comment to Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
    Int J Urol. 2020 Dec 16. doi: 10.1111/iju.14470.
    PubMed    


  22. UEMURA H, Arai G, Uemura H, Suzuki H, et al
    Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
    Int J Urol. 2020 Dec 8. doi: 10.1111/iju.14447.
    PubMed     Abstract available


    November 2020
  23. KATO M, Sasaki T, Inoue T
    Current experimental human tissue-derived models for prostate cancer research.
    Int J Urol. 2020 Nov 27. doi: 10.1111/iju.14441.
    PubMed     Abstract available


  24. SHIRAISHI K
    Editorial Comment to Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance-ultrasound image fusion systems.
    Int J Urol. 2020 Nov 24. doi: 10.1111/iju.14446.
    PubMed    


  25. YOSHIDA S, Takahara T, Yokoyama M, Matsuoka Y, et al
    Can progressive site-directed therapy prolong the efficacy of subsequent androgen receptor axis-targeted drugs in oligometastatic castration-resistant prostate cancer?
    Int J Urol. 2020 Nov 2. doi: 10.1111/iju.14421.
    PubMed    


  26. MORITA M
    Editorial Comment to Coverage of the external prostatic region by the hybrid method compared with the conventional method of prostate low-dose-rate brachytherapy: A randomized controlled study.
    Int J Urol. 2020;27:1017-1018.
    PubMed    


    October 2020
  27. SUGIURA M, Sato H, Kanesaka M, Imamura Y, et al
    Epigenetic modifications in prostate cancer.
    Int J Urol. 2020 Oct 27. doi: 10.1111/iju.14406.
    PubMed     Abstract available


  28. MATSUOKA Y, Uehara S, Yoshida S, Tanaka H, et al
    Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance-ultrasound image fusion systems.
    Int J Urol. 2020 Oct 27. doi: 10.1111/iju.14410.
    PubMed    


  29. NISHIMOTO M, Fujita K, Minami T, Yoshimura K, et al
    Editorial Comment to Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Int J Urol. 2020 Oct 17. doi: 10.1111/iju.14386.
    PubMed    


  30. HATAKEYAMA S, Ohyama C
    Response to Re: Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Oct 12. doi: 10.1111/iju.14399.
    PubMed    


  31. IWAMURA H, Hatakeyama S, Narita S, Arai Y, et al
    Prognosis of metastatic castration-resistant prostate cancer in the era of the second-generation androgen receptor-targeted agents: A retrospective multicenter study.
    Int J Urol. 2020 Oct 8. doi: 10.1111/iju.14392.
    PubMed    


  32. TAY KJ
    Editorial Comment from Dr Tay to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020;27:891-892.
    PubMed    


    September 2020
  33. SHIOTA M, Machidori A, Abe T, Monji K, et al
    Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.
    Int J Urol. 2020 Sep 15. doi: 10.1111/iju.14366.
    PubMed     Abstract available


  34. SUGIMURA R, Kawahara T, Uemura H
    Re: Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Sep 13. doi: 10.1111/iju.14371.
    PubMed    


  35. SHIGETA K, Kikuchi E, Matsushima M, Ogihara K, et al
    Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Int J Urol. 2020 Sep 6. doi: 10.1111/iju.14358.
    PubMed     Abstract available


    August 2020
  36. KANEKO M, Yip W, Abreu AL
    Editorial Comment from Dr Kaneko et al. to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 29. doi: 10.1111/iju.14362.
    PubMed    


  37. SHOJI S
    Editorial Comment from Dr Shoji to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 29. doi: 10.1111/iju.14353.
    PubMed    


  38. KAWAHARA T
    Editorial Comment to Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer.
    Int J Urol. 2020 Aug 8. doi: 10.1111/iju.14346.
    PubMed    


  39. AYDIN AM, Gage K, Dhillon J, Cheriyan SK, et al
    Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 6. doi: 10.1111/iju.14321.
    PubMed     Abstract available


    July 2020
  40. IPPOLITO D, Querques G, Pecorelli A, Perugini G, et al
    Diagnostic accuracy of multiparametric magnetic resonance imaging combined with clinical parameters in the detection of clinically significant prostate cancer: A novel diagnostic model.
    Int J Urol. 2020 Jul 25. doi: 10.1111/iju.14316.
    PubMed     Abstract available


  41. MARTELL K
    Editorial Comment to High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer.
    Int J Urol. 2020 Jul 22. doi: 10.1111/iju.14328.
    PubMed    


  42. VAN POPPEL H, Abrahamsson PA
    Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer.
    Int J Urol. 2020 Jul 13. doi: 10.1111/iju.14303.
    PubMed     Abstract available


  43. KASAHARA T, Ishizaki F, Kazama A, Yuki E, et al
    High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer.
    Int J Urol. 2020 Jul 7. doi: 10.1111/iju.14305.
    PubMed     Abstract available


  44. HAGHSHENO MA, Hammarsten J, Peeker R, Behre CJ, et al
    Men with type 2 diabetes mellitus have a lower detection rate of prostate cancer.
    Int J Urol. 2020 Jul 6. doi: 10.1111/iju.14304.
    PubMed    


    June 2020
  45. NAKAI Y, Tanaka N, Asakawa I, Anai S, et al
    Biochemical control of the combination of cyclooxygenase-2 inhibitor and (125) I-brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial.
    Int J Urol. 2020 Jun 26. doi: 10.1111/iju.14294.
    PubMed     Abstract available


  46. MOMOTA M, Hatakeyama S, Soma O, Tanaka T, et al
    Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Jun 4. doi: 10.1111/iju.14256.
    PubMed     Abstract available


    May 2020
  47. KATO M
    Editorial Comment to Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2020 May 30. doi: 10.1111/iju.14278.
    PubMed    


  48. HATAKEYAMA S, Narita S, Takahashi M, Sakurai T, et al
    Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2020 May 16. doi: 10.1111/iju.14258.
    PubMed     Abstract available


    April 2020
  49. YOSHIDA S, Takahara T, Arita Y, Toda K, et al
    Patterns of failure after progressive site-directed therapy in oligo-progressive castration-resistant prostate cancer.
    Int J Urol. 2020 Apr 14. doi: 10.1111/iju.14249.
    PubMed    


    March 2020
  50. KAWAHARA T, Miyoshi Y, Uemura H
    Re: Current treatment strategies for advanced prostate cancer.
    Int J Urol. 2020 Mar 31. doi: 10.1111/iju.14237.
    PubMed    


  51. KATO T, Sugimoto M
    Quality of life in active surveillance for early prostate cancer.
    Int J Urol. 2020 Mar 6. doi: 10.1111/iju.14202.
    PubMed     Abstract available


  52. GHAFFARI H
    Re: Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy.
    Int J Urol. 2020 Mar 5. doi: 10.1111/iju.14209.
    PubMed    


  53. TAKAHASHI S
    Editorial Comment to Treatment-induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropin-releasing hormone antagonists or agonists.
    Int J Urol. 2020 Mar 3. doi: 10.1111/iju.14214.
    PubMed    


    February 2020
  54. KIJIMA T, Ito M, Ishioka J, Matsuoka Y, et al
    Treatment-induced changes in levels of brain natriuretic peptide in prostate cancer patients receiving gonadotropin-releasing hormone antagonists or agonists.
    Int J Urol. 2020 Feb 19. doi: 10.1111/iju.14201.
    PubMed    


  55. SHIOTA M, Onozawa M, Hinotsu S, Eto M, et al
    Family history in primary hormone therapy for prostate cancer: Analysis from a community-based multi-institutional Japan-wide database.
    Int J Urol. 2020 Feb 10. doi: 10.1111/iju.14184.
    PubMed     Abstract available


  56. KITAGAWA Y
    Editorial Comment to Family history in primary hormone therapy for prostate cancer: Analysis from a community-based multi-institutional Japan-wide database.
    Int J Urol. 2020 Feb 10. doi: 10.1111/iju.14198.
    PubMed    


    January 2020
  57. UKIMURA O
    Editorial Comment from Dr Ukimura to Magnetic resonance imaging/transrectal ultrasonography fusion targeted prostate biopsy finds more significant prostate cancer in biopsy-naive Japanese men compared with the standard biopsy.
    Int J Urol. 2020 Jan 8. doi: 10.1111/iju.14168.
    PubMed    


    December 2019
  58. TAKEDA T, Tin AL, Corradi RB, Alvim R, et al
    Extensive disease among potential candidates for hemi-ablative focal therapy for prostate cancer.
    Int J Urol. 2019 Dec 13. doi: 10.1111/iju.14161.
    PubMed     Abstract available


  59. SHIOTA M
    Editorial Comment from Dr Shiota to Magnetic resonance imaging/transrectal ultrasonography fusion targeted prostate biopsy finds more significant prostate cancer in biopsy-naive Japanese men compared with the standard biopsy.
    Int J Urol. 2019 Dec 2. doi: 10.1111/iju.14156.
    PubMed    


    November 2019
  60. TAY KJ
    Editorial Comment to Focal salvage low-dose-rate brachytherapy for recurrent prostate cancer based on magnetic resonance imaging/transrectal ultrasound fusion biopsy technique.
    Int J Urol. 2019 Nov 30. doi: 10.1111/iju.14159.
    PubMed    


  61. FUJII S, Hayashi T, Honda Y, Terada H, et al
    Magnetic resonance imaging/transrectal ultrasonography fusion targeted prostate biopsy finds more significant prostate cancer in biopsy-naive Japanese men compared with the standard biopsy.
    Int J Urol. 2019 Nov 16. doi: 10.1111/iju.14149.
    PubMed     Abstract available


  62. YAMADA Y, Okihara K, Masui K, Ueno A, et al
    Focal salvage low-dose-rate brachytherapy for recurrent prostate cancer based on magnetic resonance imaging/transrectal ultrasound fusion biopsy technique.
    Int J Urol. 2019 Nov 13. doi: 10.1111/iju.14151.
    PubMed     Abstract available


  63. TSUMURA H
    Editorial Comment to Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy.
    Int J Urol. 2019 Nov 3. doi: 10.1111/iju.14148.
    PubMed    


    October 2019
  64. SHIOTA M
    Editorial Comment to Validation and development of the CHAARTED criteria in patients with hormone-naive metastatic prostate cancer: A multi-institutional retrospective study in Japan.
    Int J Urol. 2019 Oct 23. doi: 10.1111/iju.14143.
    PubMed    


  65. AKAKURA K
    Editorial Comment to Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.
    Int J Urol. 2019 Oct 21. doi: 10.1111/iju.14141.
    PubMed    


  66. OKAMOTO T, Hatakeyama S, Narita S, Arai Y, et al
    Validation and development of the CHAARTED criteria in patients with hormone-naive metastatic prostate cancer: A multi-institutional retrospective study in Japan.
    Int J Urol. 2019 Oct 15. doi: 10.1111/iju.14136.
    PubMed    


  67. NAKATA W, Yamamichi G, Tsujimura G, Tsujimoto Y, et al
    Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.
    Int J Urol. 2019 Oct 11. doi: 10.1111/iju.14135.
    PubMed    


  68. MORITA M, Fukagai T, Hirayama K, Yamatoya J, et al
    Placement of SpaceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy.
    Int J Urol. 2019 Oct 6. doi: 10.1111/iju.14123.
    PubMed     Abstract available


    September 2019
  69. TANAKA N, Asakawa I, Hasegawa M, Fujimoto K, et al
    Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan.
    Int J Urol. 2019 Sep 24. doi: 10.1111/iju.14098.
    PubMed     Abstract available


  70. NINOMIYA S, Kawahara T, Tatenuma T, Miyoshi Y, et al
    Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer.
    Int J Urol. 2019 Sep 18. doi: 10.1111/iju.14101.
    PubMed    


  71. KAWAMURA H, Kubo N, Sato H, Miyasaka Y, et al
    Quality of life in prostate cancer patients receiving particle radiotherapy: A review of the literature.
    Int J Urol. 2019 Sep 11. doi: 10.1111/iju.14102.
    PubMed     Abstract available


    August 2019
  72. MURAKAMI Y, Satoh T, Tsumura H, Tabata KI, et al
    Quality of life outcomes after low dose-rate brachytherapy for localized prostate cancer: Current status and future perspectives.
    Int J Urol. 2019 Aug 22. doi: 10.1111/iju.14090.
    PubMed     Abstract available


    July 2019
  73. KIMURA T, Koike Y, Aikawa K, Kimura S, et al
    Short-term impact of androgen deprivation therapy on bone strength in castration-sensitive prostate cancer.
    Int J Urol. 2019 Jul 28. doi: 10.1111/iju.14077.
    PubMed     Abstract available


  74. SHIGEMURA K, Fujisawa M
    Editorial Comment to Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities.
    Int J Urol. 2019 Jul 25. doi: 10.1111/iju.14085.
    PubMed    


  75. FUKUHARA S
    Editorial Comment to Erectile function recovery at 12 months after radical prostatectomy for prostate cancer is not associated with overall survival.
    Int J Urol. 2019 Jul 8. doi: 10.1111/iju.14064.
    PubMed    


  76. ISHIKAWA H, Tsuji H, Murayama S, Sugimoto M, et al
    Particle therapy for prostate cancer: The past, present and future.
    Int J Urol. 2019 Jul 8. doi: 10.1111/iju.14041.
    PubMed     Abstract available


    June 2019
  77. SEKIGUCHI A, Tsumura H, Kawakami S, Satoh T, et al
    Relationship between the dose to the bulbomembranous urethra and stricture after high dose-rate brachytherapy for prostate cancer: Matched-pair analysis.
    Int J Urol. 2019 Jun 30. doi: 10.1111/iju.14045.
    PubMed    


  78. TAKEDA T, Benfante NE, Assel M, Mulhall JP, et al
    Erectile function recovery at 12 months after radical prostatectomy for prostate cancer is not associated with overall survival.
    Int J Urol. 2019 Jun 25. doi: 10.1111/iju.14043.
    PubMed    


  79. ITO K, Oki R, Sekine Y, Arai S, et al
    Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening.
    Int J Urol. 2019 Jun 10. doi: 10.1111/iju.14039.
    PubMed     Abstract available


  80. HONGO F, Okihara K, Kitamura K, Fujihara A, et al
    Prostate cancer meeting the Japanese active surveillance criteria and diagnosed by community-based prostate-specific antigen screening: A 21-year follow-up study.
    Int J Urol. 2019 Jun 10. doi: 10.1111/iju.14037.
    PubMed     Abstract available


    May 2019
  81. NAKAMURA K, Konishi K, Komatsu T, Ishiba R, et al
    Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities.
    Int J Urol. 2019 May 26. doi: 10.1111/iju.14026.
    PubMed     Abstract available


  82. HATANO K, Tohyama N, Kodama T, Okabe N, et al
    Current status of intensity-modulated radiation therapy for prostate cancer: History, clinical results and future directions.
    Int J Urol. 2019 May 21. doi: 10.1111/iju.14011.
    PubMed     Abstract available


  83. AFFERI L, Baumeister P, Mordasini L, Mattei A, et al
    Editorial Comment to How does (68) Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?
    Int J Urol. 2019 May 13. doi: 10.1111/iju.14025.
    PubMed    


  84. BIANCHI L, Schiavina R, Borghesi M, Ceci F, et al
    How does (68) Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?
    Int J Urol. 2019 May 13. doi: 10.1111/iju.14012.
    PubMed     Abstract available


  85. YUASA T
    Editorial Comment to Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Int J Urol. 2019 May 12. doi: 10.1111/iju.14018.
    PubMed    


  86. TANAKA N, Nishimura K, Okajima E, Ina K, et al
    Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Int J Urol. 2019 May 5. doi: 10.1111/iju.14009.
    PubMed     Abstract available


    March 2019
  87. KOBAYASHI T
    Editorial Comment to Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: regulation of NCAPH by antitumor miR-199a/b-3p.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13919.
    PubMed    


    February 2019
  88. ARAI T, Kojima S, Yamada Y, Sugawara S, et al
    Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: Regulation of NCAPH by antitumor miR-199a/b-3p.
    Int J Urol. 2019 Feb 28. doi: 10.1111/iju.13911.
    PubMed     Abstract available


  89. KOGUCHI T, Haga N, Matsuoka K, Yabe M, et al
    Atherosclerosis as a predictor of transient exacerbation of overactive bladder symptoms after robot-assisted laparoscopic radical prostatectomy.
    Int J Urol. 2019;26:234-240.
    PubMed     Abstract available


    December 2018
  90. INOUE T
    Editorial Comment to Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
    Int J Urol. 2018 Dec 21. doi: 10.1111/iju.13887.
    PubMed    


  91. DING XF, Huang TB, Gao Y, Lu SM, et al
    Permanent (125) I prostate brachytherapy for castration-resistant prostate cancer.
    Int J Urol. 2018 Dec 4. doi: 10.1111/iju.13866.
    PubMed     Abstract available


    November 2018
  92. INOUE Y, Ushijima S, Shiraishi T, Fujihara A, et al
    Biochemical and magnetic resonance image response in targeted focal cryotherapy to ablate targeted biopsy-proven index lesion of prostate cancer.
    Int J Urol. 2018 Nov 28. doi: 10.1111/iju.13857.
    PubMed    


  93. SHIOTA M, Namitome R, Kobayashi T, Inokuchi J, et al
    Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
    Int J Urol. 2018 Nov 21. doi: 10.1111/iju.13870.
    PubMed    


  94. HAKOZAKI Y, Matsushima H, Murata T, Masuda T, et al
    Detection rate of clinically significant prostate cancer in magnetic resonance imaging and ultrasonography-fusion transperineal targeted biopsy for lesions with a prostate imaging reporting and data system version 2 score of 3-5.
    Int J Urol. 2018 Nov 21. doi: 10.1111/iju.13842.
    PubMed     Abstract available


  95. PATEL DN, Chapin BF, Freedland SJ
    Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Int J Urol. 2018 Nov 20. doi: 10.1111/iju.13861.
    PubMed    


  96. HAYASHI T, Fujita K, Matsushita M, Hayashi Y, et al
    Metformin inhibits prostate cancer growth induced by a high-fat diet in Pten-deficient model mice.
    Int J Urol. 2018 Nov 20. doi: 10.1111/iju.13847.
    PubMed    


    October 2018
  97. SAVELLI G, Zaniboni A, Stefanelli A
    Re: Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
    Int J Urol. 2018 Oct 24. doi: 10.1111/iju.13832.
    PubMed    


  98. POELAERT F, Schatteman P, Lumen N
    Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Int J Urol. 2018 Oct 22. doi: 10.1111/iju.13837.
    PubMed    


    September 2018
  99. AFRIANSYAH A, Hamid ARA, Mochtar CA, Umbas R, et al
    Survival analysis and development of a prognostic nomogram for bone-metastatic prostate cancer patients: A single-center experience in Indonesia.
    Int J Urol. 2018 Sep 30. doi: 10.1111/iju.13813.
    PubMed     Abstract available


  100. YANO A, Kawakami S
    Re: Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018 Sep 30. doi: 10.1111/iju.13809.
    PubMed    


  101. PATEL DN, Jha S, Howard LE, Amling CL, et al
    Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Int J Urol. 2018 Sep 25. doi: 10.1111/iju.13806.
    PubMed     Abstract available


  102. SCHIAVINA R, Chessa F, Borghesi M, Gaudiano C, et al
    State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer.
    Int J Urol. 2018 Sep 20. doi: 10.1111/iju.13797.
    PubMed     Abstract available


  103. CHOI SY, Ryu J, You D, Hong JH, et al
    Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
    Int J Urol. 2018 Sep 20. doi: 10.1111/iju.13800.
    PubMed     Abstract available


    August 2018
  104. FUJITA K, Nonomura N
    Urinary biomarkers of prostate cancer.
    Int J Urol. 2018 Aug 21. doi: 10.1111/iju.13734.
    PubMed     Abstract available


  105. REINSTATLER L, Carmichael D, Austin AM, Goodney PP, et al
    Regional variation in the intensity of prostate cancer care: A study of a large Medicare sample.
    Int J Urol. 2018 Aug 13. doi: 10.1111/iju.13775.
    PubMed    


    July 2018
  106. KANAO K, Kajikawa K, Kobayashi I, Morinaga S, et al
    Impact of a novel biopsy instrument with a 25-mm side-notch needle on the detection of prostate cancer in transrectal biopsy.
    Int J Urol. 2018 Jul 18. doi: 10.1111/iju.13722.
    PubMed     Abstract available


    June 2018
  107. SAKAMOTO S
    Editorial Comment to Epidemiology of prostate cancer in Asian countries.
    Int J Urol. 2018;25:531-532.
    PubMed    


    May 2018
  108. YANO A, Arai Y, Kitayama S, Otsuka Y, et al
    Effect of zoledronic acid dosing every 3 months in patients with prostate cancer with skeletal metastases: A multicenter prospective exploratory study with matched historical controls.
    Int J Urol. 2018 May 14. doi: 10.1111/iju.13703.
    PubMed    


  109. CHEN PY, Chiang PH, Liu YY, Chuang YC, et al
    Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence.
    Int J Urol. 2018 May 13. doi: 10.1111/iju.13581.
    PubMed     Abstract available


  110. KIMURA T, Egawa S
    Epidemiology of prostate cancer in Asian countries.
    Int J Urol. 2018 May 8. doi: 10.1111/iju.13593.
    PubMed     Abstract available


  111. SAKAMOTO S
    Editorial Comment to Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018;25:403-404.
    PubMed    


    April 2018
  112. MITSUI Y
    Editorial Comment to Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Sca
    Int J Urol. 2018 Apr 16. doi: 10.1111/iju.13582.
    PubMed    


  113. MEARINI L
    Editorial Comment to Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13575.
    PubMed    


  114. KITAGAWA Y
    Editorial Comment to Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13578.
    PubMed    


  115. IZUMI K
    Editorial Comment to Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13572.
    PubMed    


  116. TAKAMOTO A, Tanimoto R, Bekku K, Araki M, et al
    Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13555.
    PubMed     Abstract available


  117. NAKAJIMA K, Kaneko G, Takahashi S, Matsuyama H, et al
    Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI)
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13556.
    PubMed     Abstract available


  118. HASHIMOTO T, Ohori M, Shimodaira K, Kaburaki N, et al
    Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13563.
    PubMed     Abstract available


  119. BIANCHI L, Schiavina R, Borghesi M, Bianchi FM, et al
    Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database.
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13565.
    PubMed     Abstract available


    March 2018
  120. OKIHARA K
    Editorial Comment to Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.
    Int J Urol. 2018 Mar 25. doi: 10.1111/iju.13570.
    PubMed    


  121. TILKI D, Pompe RS, Bandini M, Marchioni M, et al
    Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018 Mar 23. doi: 10.1111/iju.13535.
    PubMed     Abstract available


  122. HAKARIYA T, Shida Y, Tsurusaki T, Watanabe J, et al
    Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
    Int J Urol. 2018 Mar 8. doi: 10.1111/iju.13542.
    PubMed     Abstract available


  123. ALBERTS AR, Roobol MJ
    Editorial Comment to Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
    Int J Urol. 2018;25:277.
    PubMed    


    February 2018
  124. KIKKAWA K, Iba A, Kohjimoto Y, Noda Y, et al
    Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.
    Int J Urol. 2018 Feb 4. doi: 10.1111/iju.13530.
    PubMed     Abstract available


  125. AKAMATSU S, Inoue T, Ogawa O, Gleave ME, et al
    Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
    Int J Urol. 2018 Feb 3. doi: 10.1111/iju.13526.
    PubMed     Abstract available


    January 2018
  126. BEGEMANN D, Anastos H, Kyprianou N
    Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Int J Urol. 2018 Jan 17. doi: 10.1111/iju.13505.
    PubMed     Abstract available


  127. SAKAMOTO S
    Editorial Comment to Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Int J Urol. 2018 Jan 17. doi: 10.1111/iju.13510.
    PubMed    


  128. TAKEI A, Sakamoto S, Wakai K, Tamura T, et al
    Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
    Int J Urol. 2018 Jan 11. doi: 10.1111/iju.13521.
    PubMed     Abstract available


  129. MURATA Y, Tatsugami K, Yoshikawa M, Hamaguchi M, et al
    Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer.
    Int J Urol. 2018 Jan 8. doi: 10.1111/iju.13514.
    PubMed     Abstract available


    December 2017
  130. KOMURA K, Sweeney CJ, Inamoto T, Ibuki N, et al
    Current treatment strategies for advanced prostate cancer.
    Int J Urol. 2017 Dec 20. doi: 10.1111/iju.13512.
    PubMed     Abstract available


  131. NEUPANE S, Steyerberg E, Raitanen J, Talala K, et al
    Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
    Int J Urol. 2017 Dec 10. doi: 10.1111/iju.13508.
    PubMed     Abstract available


    November 2017
  132. NAKANO M, Araki H, Ohtakara K, Tanaka H, et al
    Significance of total colonoscopy screening before definitive radiotherapy for prostate cancer on the detection of anorectocolonic disease requiring intervention in advance.
    Int J Urol. 2017 Nov 23. doi: 10.1111/iju.13494.
    PubMed    


    October 2017
  133. YANO A, Kagawa M, Takeshita H, Okada Y, et al
    Improved survival of men with metastatic prostate cancer treated with androgen deprivation therapy plus radiotherapy to the prostate.
    Int J Urol. 2017 Oct 23. doi: 10.1111/iju.13479.
    PubMed    


  134. MITSUZUKA K, Arai Y
    Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
    Int J Urol. 2017 Oct 20. doi: 10.1111/iju.13473.
    PubMed     Abstract available


    September 2017
  135. SAIKA T, Miura N, Fukumoto T, Yanagihara Y, et al
    Role of robot-assisted radical prostatectomy in locally advanced prostate cancer.
    Int J Urol. 2017 Sep 13. doi: 10.1111/iju.13441.
    PubMed     Abstract available


  136. PEREIRA-AZEVEDO N, Braga I, Verbeek JF, Osorio L, et al
    Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator.
    Int J Urol. 2017 Sep 13. doi: 10.1111/iju.13442.
    PubMed     Abstract available


  137. YANO A, Kagawa M, Takeshita H, Okada Y, et al
    Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naive prostate cancer with skeletal metastases.
    Int J Urol. 2017 Sep 11. doi: 10.1111/iju.13445.
    PubMed    


    August 2017
  138. SAKAMOTO S
    Editorial Comment to Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).
    Int J Urol. 2017 Aug 20. doi: 10.1111/iju.13436.
    PubMed    


  139. SAKAMOTO S
    Editorial Comment to Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer.
    Int J Urol. 2017 Aug 6. doi: 10.1111/iju.13433.
    PubMed    


    July 2017
  140. DINH KT, Yang DD, Nead KT, Reznor G, et al
    Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer.
    Int J Urol. 2017 Jul 22. doi: 10.1111/iju.13409.
    PubMed     Abstract available


  141. KAKEHI Y, Sugimoto M, Taoka R
    Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).
    Int J Urol. 2017 Jul 1. doi: 10.1111/iju.13380.
    PubMed     Abstract available


    June 2017
  142. NOGUCHI M, Koga N, Igawa T, Itoh K, et al
    Clinical development of immunotherapy for prostate cancer.
    Int J Urol. 2017 Jun 21. doi: 10.1111/iju.13397.
    PubMed     Abstract available


  143. MCGINLEY KF, Sun X, Howard LE, Aronson WJ, et al
    Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.
    Int J Urol. 2017 Jun 6. doi: 10.1111/iju.13387.
    PubMed     Abstract available


  144. MIZOKAMI A, Kadono Y, Kitagawa Y, Izumi K, et al
    Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
    Int J Urol. 2017 Jun 3. doi: 10.1111/iju.13372.
    PubMed     Abstract available


    May 2017
  145. ENATSU N
    Editorial Comment to Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Impl
    Int J Urol. 2017 May 31. doi: 10.1111/iju.13383.
    PubMed    


  146. NAKAJIMA K, Edenbrandt L, Mizokami A
    Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer.
    Int J Urol. 2017 May 26. doi: 10.1111/iju.13386.
    PubMed     Abstract available


  147. MITSUZUKA K
    Editorial comment to Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 May 21. doi: 10.1111/iju.13379.
    PubMed    


  148. YUASA T
    Editorial Comment to Identification of risk factors predicting febrile neutropenia in patients with metastatic germ cell tumors receiving cisplatin-based combination chemotherapy.
    Int J Urol. 2017 May 6. doi: 10.1111/iju.13365.
    PubMed    


    April 2017
  149. TERADA N, Maughan BL, Akamatsu S, Kobayashi T, et al
    Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13346.
    PubMed     Abstract available


  150. OKIHARA K, Yorozu A, Saito S, Tanaka N, et al
    Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13358.
    PubMed     Abstract available


  151. NISHIKAWA M, Miyake H, Fujisawa M
    Identification of risk factors predicting febrile neutropenia in patients with metastatic germ cell tumors receiving cisplatin-based combination chemotherapy.
    Int J Urol. 2017 Apr 18. doi: 10.1111/iju.13352.
    PubMed     Abstract available


    March 2017
  152. NARAYAN VM, Konety BR, Warlick C
    Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
    Int J Urol. 2017 Mar 27. doi: 10.1111/iju.13326.
    PubMed     Abstract available


    September 2016
  153. KAMADA S
    Editorial Comment to Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy.
    Int J Urol. 2016 Sep 7. doi: 10.1111/iju.13195.
    PubMed    


    August 2016
  154. MOROTE J, Comas I, Planas J, Celma A, et al
    Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy.
    Int J Urol. 2016 Aug 3. doi: 10.1111/iju.13180.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: